Keywords: first, filings, gw, amprenavir, glaxo, wellcome, submitted
First Filings For GW's Amprenavir
Article | 20 October 1998
Glaxo Wellcome has submitted its first regulatory dossiers forAgenerase (amprenavir), a second-generation HIV protease inhibitor with a twice-daily dosing regimen, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
